Solid Tumor Malignancies study: CP-383
Official title Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
ClinicalTrials.gov ID: NCT07030257
What this study is testing
What is CP-383?
an investigational oral medicine being studied for solid tumor malignancies is designed to inhibit pyrimidine synthesis in cancer cells
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether CP-383 can slow or stop tumor growth and how safe it is.
- Who it's for
- You may be able to join if you have advanced or metastatic solid tumors such as colon, lung, head and neck, bladder, or pancreatic cancer.
- What's involved
- You would take CP-383 by mouth every day. You would visit the clinic weekly for the first 6 weeks, then every 3 weeks for check‑ups and tests.
- Time commitment
- The study lasts until the doctors see if the drug works, with visits for several months.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Measurable or non measurable cancer that the research can assess for changes
- Not eligible or able to take existing standard therapies for cancer
- Availability of a part of a tumor for laboratory testing or willing to have a safe biopsy taken from a tumor
- Diagnosed with locally advanced, recurrent or metastatic incurable disease
- Part 1: any solid tumor (with the exception of brain cancer) that has progressed, standard therapy is no longer or has not helped the cancer, or is...
You likely can't join if
- Inability to swallow pills
- Known history of HIV, HCV, HBV unless cured, controlled with undetectable viral load
- Active tumor in the brain
- Clinically significant liver disease
- Significant gastrointestinal diseases
- History of other cancer within past 5 years with certain exceptions for cancers that are likely cured
See the full eligibility criteria
- Measurable or non measurable cancer that the research can assess for changes
- Not eligible or able to take existing standard therapies for cancer
- Availability of a part of a tumor for laboratory testing or willing to have a safe biopsy taken from a tumor
- Diagnosed with locally advanced, recurrent or metastatic incurable disease
- Part 1: any solid tumor (with the exception of brain cancer) that has progressed, standard therapy is no longer or has not helped the cancer, or is too toxic and for whom a clinical trial is an option for continued...
- Part 1: specific advanced, metastatic tumor types will also be enrolled: colorectal cancer, small cell lung cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer - some of these...
- Part 1: selected solid tumor cancer types (with the exception of brain cancers) that have a specific gene mutation in the cancer
- Part 2: specific advanced, metastatic tumor types will also be enrolled: colorectal cancer, small cell lung cancer, head and neck cancer - some of these will have a specific gene mutation in the cancer \_ Part 2...
- Adequate blood and urine lab tests
- Women and men of childbearing potential with adequate contraception
- Provides written informed consent
- Willing to comply with the requirements of the protocol
- Inability to swallow pills
- Known history of HIV, HCV, HBV unless cured, controlled with undetectable viral load
- Active tumor in the brain
- Clinically significant liver disease
- Significant gastrointestinal diseases
- History of other cancer within past 5 years with certain exceptions for cancers that are likely cured
- Significant cardiac disease
- Other diseases that are not well controlled that could make taking the drug unsafe
- pregnant or lactating females
- Exposure to certain anti-cancer or other drugs within a certain period before the start of study drug
The study team makes the final eligibility decision.
Where it is enrolling
- Denver, Colorado, United States
- Orlando, Florida, United States
- Grand Rapids, Michigan, United States
- St Louis, Missouri, United States
- Omaha, Nebraska, United States
- Huntersville, North Carolina, United States
- Cleveland, Ohio, United States
- Maumee, Ohio, United States
- Philadelphia, Pennsylvania, United States
- Dallas, Texas, United States
- San Antonio, Texas, United States
- West Valley City, Utah, United States
- Fairfax, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Denver, Colorado, United States; Orlando, Florida, United States; Grand Rapids, Michigan, United States; St Louis, Missouri, United States; Omaha, Nebraska, United States; Huntersville, North Carolina, United States and 7 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.